Burning Rock Biotech Ltd ADR Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.23 Intrinsic Value $13.63median of 2 methodsbased on filings through 31 Dec 2025 Market Price $15.99Price as of 1 Oct 2026 Near fair valueIntrinsic value is 15% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $168.6M Enterprise Value $100.5M Shares Outstanding 10.5M diluted Next Earnings Date10 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Burning Rock Biotech is navigating a challenging transition from a centralized laboratory testing model to an in-hospital testing model in China's precision oncology market. While the company has successfully reduced operating expenses and improved gross margins in key segments, it continues to face double-digit year-over-year revenue declines and persistent net losses. The founder's recent open-market purchases of ADSs signal strong internal confidence, but near-term commercial headwinds and cash burn warrant a cautious Hold recommendation until revenue stabilization and a clear path to profitability are established. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $3.72 Pharma R&D services and central laboratory revenues continue to decline faster than in-hospital sales can grow. Regulatory delays in product registrations and intense domestic competition from local diagnostic players compress margins, accelerating cash burn and forcing dilutive capital raises. Base CaseCentral scenario $6.74 In-hospital testing remains the primary revenue driver with stable single-digit growth, offsetting the planned decline in central laboratory testing. Cost-control measures keep quarterly net losses manageable, and the company maintains a stable cash runway of over RMB 400 million without immediate dilutive financing. Bull CaseUpside scenario $12.24 The transition to the in-hospital model accelerates, driving higher-margin kit sales and regulatory approvals for companion diagnostics. Strong clinical validation of the early cancer detection platform (ELSA-seq) leads to commercial partnerships and milestone payments, significantly reducing cash burn and restoring double-digit revenue growth. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |